Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders

R. Juza, P. Vlcek, E. Mezeiova, K. Musilek, O. Soukup, J. Korabecny

. 2020 ; 40 (5) : 1593-1678. [pub] 20200301

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004862

Serotonin (5-hydroxytryptophan [5-HT]) is a biologically active amine expressed in platelets, in gastrointestinal (GI) cells and, to a lesser extent, in the central nervous system (CNS). This biogenic compound acts through the activation of seven 5-HT receptors (5-HT1-7 Rs). The 5-HT3 R is a ligand-gated ion channel belonging to the Cys-loop receptor family. There is a wide variety of 5-HT3 R modulators, but only receptor antagonists (known as setrons) have been used clinically for chemotherapy-induced nausea and vomiting and irritable bowel syndrome treatment. However, since the discovery of the setrons in the mid-1980s, a large number of studies have been published exploring new potential applications due their potency in the CNS and mild side effects. The results of these studies have revealed new potential applications, including the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety, and drug abuse. In this review, we provide information related to therapeutic potential of 5-HT3 R antagonists on GI and neuropsychiatric disorders. The major attention is paid to the structure, function, and pharmacology of novel 5-HT3 R modulators developed over the past 10 years.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004862
003      
CZ-PrNML
005      
20221014093459.0
007      
ta
008      
220113s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/med.21666 $2 doi
035    __
$a (PubMed)32115745
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Juza, Radomir $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
245    10
$a Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders / $c R. Juza, P. Vlcek, E. Mezeiova, K. Musilek, O. Soukup, J. Korabecny
520    9_
$a Serotonin (5-hydroxytryptophan [5-HT]) is a biologically active amine expressed in platelets, in gastrointestinal (GI) cells and, to a lesser extent, in the central nervous system (CNS). This biogenic compound acts through the activation of seven 5-HT receptors (5-HT1-7 Rs). The 5-HT3 R is a ligand-gated ion channel belonging to the Cys-loop receptor family. There is a wide variety of 5-HT3 R modulators, but only receptor antagonists (known as setrons) have been used clinically for chemotherapy-induced nausea and vomiting and irritable bowel syndrome treatment. However, since the discovery of the setrons in the mid-1980s, a large number of studies have been published exploring new potential applications due their potency in the CNS and mild side effects. The results of these studies have revealed new potential applications, including the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety, and drug abuse. In this review, we provide information related to therapeutic potential of 5-HT3 R antagonists on GI and neuropsychiatric disorders. The major attention is paid to the structure, function, and pharmacology of novel 5-HT3 R modulators developed over the past 10 years.
650    12
$a gastrointestinální nemoci $x farmakoterapie $7 D005767
650    _2
$a lidé $7 D006801
650    _2
$a nauzea $7 D009325
650    _2
$a receptory serotoninové 5-HT3 $7 D044406
650    12
$a serotonin $7 D012701
650    _2
$a antagonisté serotoninu $x farmakologie $7 D012702
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Vlcek, Premysl $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mezeiová, Eva $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $7 xx0277560
700    1_
$a Musilek, Kamil $u Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Korabecny, Jan $u National Institute of Mental Health, Klecany, Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 40, č. 5 (2020), s. 1593-1678
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32115745 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20221014093452 $b ABA008
999    __
$a ok $b bmc $g 1752157 $s 1156011
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 40 $c 5 $d 1593-1678 $e 20200301 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
LZP    __
$a Pubmed-20220113
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace